title: ABH blood group isoantigen expression in breast carcinomas--an immunohistochemical evaluation using monoclonal antibodies.
abstract: The ABH blood group isoantigen status of a retrospective series of 233 invasive breast carcinomas was examined, employing monoclonal antibodies (MCAB) against A, B, and H antigens with the avidin-biotin-peroxidase complex method. In addition, the H antigen was localized with Ulex Europeus Agglutinin I (UEAI) binding. The MCABs provided consistent and specific staining of erythrocytes and endothelium, as well as normal and neoplastic breast epithelium. The anti-H MCAB yielded cleaner background and less intense staining, but otherwise the staining distribution was comparable to the UEA I technique. Contrary to previous reports, deletion of isoantigen expression was not universal in all invasive carcinomas. Whereas 64%, 77%, and 73% of carcinomas from groups A, B, and AB patients, respectively, demonstrated total isoantigen loss, the remaining tumors exhibited variable degrees of isoantigen expression. Moreover, those carcinomas with complete loss of A and B determinants still displayed variable degrees of H immunoreactivity. Carcinomas from group O patients had different degrees of H antigen deletion, with only 12% showing total loss. Statistical analysis revealed that the isoantigen status bore no significant relationship to various epidemiologic, clinical, and pathologic parameters and did not serve as a useful prognostic determinant.
authors.forename: A K
authors.initials: AK
authors.lastname: Lee
authors.forename: R A
authors.initials: RA
authors.lastname: DeLellis
authors.forename: P P
authors.initials: PP
authors.lastname: Rosen
authors.forename: P E
authors.initials: PE
authors.lastname: Saigo
authors.forename: M D
authors.initials: MD
authors.lastname: Gangi
authors.forename: R
authors.initials: R
authors.lastname: Bagin
authors.forename: S
authors.initials: S
authors.lastname: Groshen
authors.forename: H J
authors.initials: HJ
authors.lastname: Wolfe
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D002288:Adenocarcinoma, Mucinous / Q000276:immunology / Q000473:pathology; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology; D002277:Carcinoma / Q000276:immunology / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000276:immunology / Q000473:pathology; D002291:Carcinoma, Papillary / Q000276:immunology / Q000473:pathology; D000939:Epitopes / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007519:Isoantigens / Q000032:analysis*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D000939:Epitopes; D007519:Isoantigens